Research progress on efficacy and influencing factors of postoperative radiotherapy for stage ⅢA(N 2) non-small cell lung cancer

VernacularTitle:ⅢA（N 2）期非小细胞肺癌辅助放疗疗效影响因素的研究进展
Author: Lixian LING ¹ ; Jianfei FU
Author Information

1. 浙江大学医学院附属金华医院肿瘤内科，金华　321000
Keywords: Carcinoma, non-small cell lung, stage ⅢA(N 2); Postoperative radiotherapy; Research report
From: Chinese Journal of Radiation Oncology 2022;31(10):944-948
CountryChina
Language:Chinese
Abstract: Non-small cell lung cancer(NSCLC) is highly malignant and has poor prognosis, in which stage ⅢA(N 2) NSCLC approximately accounts for 20%. Patients with stage ⅢA(N 2) NSCLC have high heterogeneity and distinct survival difference. Loco-regional recurrence and distant metastasis are the main causes of treatment failure. At present, whether stage ⅢA(N 2) NSCLC patients should receive postoperative radiotherapy(PORT) remains controversial. Such patients still lack high level proof to receive PORT.